Skip to content
Peptide research

DA-1726

Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

DA-1726 is an experimental dual GLP-1/glucagon agonist studied for weight loss and liver fat reduction. The case rests on one small Phase 1 trial: weight and waist losses look promising, but glucose and liver-stiffness signals are weak, with no larger trials yet. GI effects are common, and its glucagon activity carries a theoretical risk of raising blood sugar. Not an approved drug, with no long-term safety data and only unregulated research-grade supply.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Robust early weight loss (9.1% at 8 weeks without dose titration)

    Medium

    Small randomized Phase 1 trial; the 8-week extension figure lacked a placebo comparison.

  • Significant waist circumference reduction (9.8 cm at Day 54) suggesting visceral fat targeting

    Medium

    Placebo-controlled human data on waist size; visceral fat targeting is inferred, not measured directly.

  • Fasting glucose improvement (12.3 mg/dL from baseline of 105.3 mg/dL)

    Low

    Single small study, no placebo comparison reported, from a near-normal baseline glucose level.

Evidence limits

Evidence Level
Early Evidence (Phase 1)

DA-1726 has completed Phase 1 single and multiple ascending dose cohorts. The 48 mg non-titrated cohort showed 9.1% weight loss at 8 weeks with no serious adverse events or treatment-related discontinuations. However, only small numbers of participants have been studied (approximately 9 per cohort), and no Phase 2 or Phase 3 data are available. Phase 1 Part 3 began in April 2026; dose-titration completion was announced in July, with 16-week results expected in Q4 2026.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(3)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Gastrointestinal adverse events (mild to moderate)

    Moderate
  • Very limited clinical data (Phase 1 only)

    High
  • Glucagon-mediated hyperglycemia risk (theoretical)

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.